Search Results - "Crossman, Alan R."

Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease by Cenci, M. Angela, Crossman, Alan R.

“…ABSTRACT Understanding the biological mechanisms of l‐dopa‐induced motor complications is dependent on our ability to investigate these phenomena in animal…”
Get full text

Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections by Shariatgorji, Mohammadreza, Nilsson, Anna, Goodwin, Richard J.A., Källback, Patrik, Schintu, Nicoletta, Zhang, Xiaoqun, Crossman, Alan R., Bezard, Erwan, Svenningsson, Per, Andren, Per E.

“…Current neuroimaging techniques have very limited abilities to directly identify and quantify neurotransmitters from brain sections. We have developed a…”
Get full text

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease by Kobylecki, Christopher, Cenci, M. Angela, Crossman, Alan R, Ravenscroft, Paula

“…J. Neurochem. (2010) 114, 409-511. Overactivity of striatal α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors is implicated in…”
Get full text

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease by Kobylecki, Christopher, Hill, Michael P., Crossman, Alan R., Ravenscroft, Paula

“…L‐Dopa‐induced dyskinesia in patients with Parkinson's disease can be alleviated by amantadine, an antagonist at N‐methyl‐D‐aspartate glutamate receptors. The…”
Get full text

role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease by van der Stelt, Mario, Fox, Susan H, Hill, Michael, Crossman, Alan R, Petrosino, Stefania, Di Marzo, Vincenzo, Brotchie, Jonathan M

“…ABSTRACTEndocannabinoids and cannabinoid CB1 receptors play a role in the control of movement by modulating GABA, glutamate, and other neurotransmitters…”
Get full text

Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l -DOPA-induced dyskinesia by Bourdenx, Mathieu, Nilsson, Anna, Wadensten, Henrik, Fälth, Maria, Li, Qin, Crossman, Alan R, Andrén, Per E, Bezard, Erwan

“…Abstract A role for enhanced peptidergic transmission, either opioidergic or not, has been proposed for the generation of l -3,4-dihydroxyphenylalanine ( l…”
Get full text

Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease by Bezard, Erwan, Dovero, Sandra, Prunier, Caroline, Ravenscroft, Paula, Chalon, Sylvie, Guilloteau, Denis, Crossman, Alan R, Bioulac, Bernard, Brotchie, Jonathan M, Gross, Christian E

“…The concept of a threshold of dopamine (DA) depletion for onset of Parkinson's disease symptoms, although widely accepted, has, to date, not been determined…”
Get full text

RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease by Ko, Wai Kin D, Martin-Negrier, Marie-Laure, Bezard, Erwan, Crossman, Alan R, Ravenscroft, Paula

“…Abstract Regulators of G-protein signalling (RGS) proteins are implicated in striatal G-protein coupled receptor (GPCR) sensitisation in the pathophysiology of…”
Get full text

Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure by Scholz, Birger, Svensson, Marcus, Alm, Henrik, Sköld, Karl, Fälth, Maria, Kultima, Kim, Guigoni, Céline, Doudnikoff, Evelyne, Li, Qin, Crossman, Alan R, Bezard, Erwan, Andrén, Per E

“…L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a…”
Get full text

µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease by Bezard, Erwan, Li, Qin, Hulme, Heather, Fridjonsdottir, Elva, Nilsson, Anna, Pioli, Elsa, Andren, Per E, Crossman, Alan R

“…Parkinson's disease (PD) is characterized by severe locomotor deficits and is commonly treated with the dopamine precursor L-DOPA, but its prolonged usage…”
Get full text

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease by Bastide, Matthieu F, Meissner, Wassilios G, Picconi, Barbara, Fasano, Stefania, Fernagut, Pierre-Olivier, Feyder, Michael, Francardo, Veronica, Alcacer, Cristina, Ding, Yunmin, Brambilla, Riccardo, Fisone, Gilberto, Jon Stoessl, A, Bourdenx, Mathieu, Engeln, Michel, Navailles, Sylvia, De Deurwaerdère, Philippe, Ko, Wai Kin D, Simola, Nicola, Morelli, Micaela, Groc, Laurent, Rodriguez, Maria-Cruz, Gurevich, Eugenia V, Quik, Maryka, Morari, Michele, Mellone, Manuela, Gardoni, Fabrizio, Tronci, Elisabetta, Guehl, Dominique, Tison, François, Crossman, Alan R, Kang, Un Jung, Steece-Collier, Kathy, Fox, Susan, Carta, Manolo, Angela Cenci, M, Bézard, Erwan

“…Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced…”
Get full text

Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease by Scheller, Dieter, Chan, Piu, Li, Qin, Wu, Tao, Zhang, Renling, Guan, Le, Ravenscroft, Paula, Guigoni, Celine, Crossman, Alan R., Hill, Michael, Bezard, Erwan

“…Clinical DA agonist monotherapy trials, which used in vivo imaging of the DA transporter (DAT) to assess the rate of progression of nigrostriatal degeneration,…”
Get full text

Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia by Ravenscroft, Paula, Chalon, Sylvie, Brotchie, Jonathan M., Crossman, Alan R.

“…The dopamine precursor, l-3,4-dihydroxyphenylalanine ( l-DOPA), remains the most common treatment for Parkinson's disease. However, following long-term…”
Get full text

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease by Segovia, Gregorio, Mora, Francisco, Crossman, Alan R., Brotchie, Jonathan M.

“…The present study was designed to determine the potential of CB1 cannabinoid receptor modulating compounds in the treatment of L‐3,4‐dihydroxyphenylalanine…”
Get full text

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease by Hill, Michael P, Ravenscroft, Paula, Bezard, Erwan, Crossman, Alan R, Brotchie, Jonathan M, Michel, Anne, Grimée, Renee, Klitgaard, Henrik

“…Levetiracetam (LEV) (Keppra; UCB Pharma, Brussels, Belgium) has recently been reported to have antidyskinetic activity against levodopa (L-DOPA)-induced…”
Get more information

Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE by Kultima, Kim, Scholz, Birger, Alm, Henrik, Sköld, Karl, Svensson, Marcus, Crossman, Alan R, Bezard, Erwan, Andrén, Per E, Lönnstedt, Ingrid

“…Two-Dimensional Difference In Gel Electrophoresis (2D-DIGE) is a powerful tool for measuring differences in protein expression between samples or conditions…”
Get full text

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset by Hill, Michael P., Bezard, Erwan, McGuire, Steven G., Crossman, Alan R., Brotchie, Jonathan M., Michel, Ann, Grimée, Renee, Klitgaard, Henrik

“…Long‐term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus…”
Get full text

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia by Kobylecki, Christopher, Crossman, Alan R., Ravenscroft, Paula

“…Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic…”
Get full text

Functions of the basal ganglia-paradox or no paradox? by Crossman, Alan R., Obeso, Jose A.

Get full text

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia by Fridjonsdottir, Elva, Shariatgorji, Reza, Nilsson, Anna, Vallianatou, Theodosia, Odell, Luke R, Schembri, Luke S, Svenningsson, Per, Fernagut, Pierre-Olivier, Crossman, Alan R, Bezard, Erwan, Andrén, Per E

“…l-DOPA treatment for Parkinson's disease frequently leads to dyskinesias, the pathophysiology of which is poorly understood. We used MALDI-MSI to map the…”
Get full text